Zynerba Pharmaceuticals, Inc. (ZYNE)
Stock Price:
$3.65 USD
-0.20 (-5.19%)
Updated Oct 19, 2020 11:08 AM EDT - Market open
Key Info
| Market Cap |
106.78M |
| Revenue (ttm) |
86,000 |
| Net Income (ttm) |
-45.33M |
| Shares Out |
29.26M |
| EPS (ttm) |
-1.89 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$3.65 |
| Previous Close |
$3.85 |
| Change ($) |
-0.20 |
| Change (%) |
-5.19% |
| Day's Open |
3.89 |
| Day's Range |
3.61 - 3.92 |
| Day's Volume |
316,890 |
| 52-Week Range |
2.55 - 8.83 |
More Stats
| Market Cap |
106.78M |
| Enterprise Value |
30.01M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
29.26M |
| Float |
27.12M |
| EPS (basic) |
-1.86 |
| EPS (diluted) |
-1.89 |
| FCF / Share |
-1.56 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.38M |
| Short Ratio |
8.60 |
| Short % of Float |
16.16% |
| Beta |
2.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1,241.65 |
| PB Ratio |
1.51 |
| Revenue |
86,000 |
| Operating Income |
-45.98M |
| Net Income |
-45.33M |
| Free Cash Flow |
-40.57M |
| Net Cash |
76.77M |
| Net Cash / Share |
2.62 |
| Gross Margin |
n/a |
| Operating Margin |
-53,469.32% |
| Profit Margin |
n/a |
| FCF Margin |
-47,178.87% |
| ROA |
-31.40% |
| ROE |
-56.66% |
| ROIC |
-1,057.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
5 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.00*
(173.97% upside)
Low
4.50
Current: $3.65
High
15.00
Target: 10.00
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | 0.09 | - | 0.01 | 0.28 | 0.81 | 0.94 |
| Revenue Growth | - | - | - | -97.4% | -65.57% | -14.18% | - |
| Gross Profit | - | 0.09 | - | 0.01 | 0.28 | 0.81 | 0.94 |
| Operating Income | -34.32 | -40.40 | -32.82 | -23.21 | -12.53 | -5.67 | -0.63 |
| Net Income | -32.94 | -39.91 | -32.01 | -23.39 | -12.55 | -5.67 | -0.64 |
| Shares Outstanding | 22.00 | 15.31 | 12.91 | 9.07 | 4.46 | 0.89 | 0.49 |
| Earnings Per Share | -1.50 | -2.61 | -2.48 | -2.58 | -2.82 | -6.44 | -1.63 |
| Operating Cash Flow | -34.82 | -32.40 | -25.84 | -20.44 | -9.79 | -3.54 | -0.12 |
| Capital Expenditures | -0.13 | -0.29 | -0.12 | -0.11 | -0.22 | -0.02 | - |
| Free Cash Flow | -34.95 | -32.68 | -25.96 | -20.55 | -10.00 | -3.56 | -0.12 |
| Cash & Equivalents | 70.06 | 59.76 | 62.51 | 30.97 | 41.51 | 9.33 | 0.15 |
| Total Debt | 0.35 | - | - | - | - | - | 0.50 |
| Net Cash / Debt | 69.71 | 59.76 | 62.51 | 30.97 | 41.51 | 9.33 | -0.35 |
| Assets | 87.76 | 67.33 | 69.05 | 36.55 | 43.64 | 11.62 | 1.86 |
| Liabilities | 12.17 | 9.73 | 8.10 | 6.97 | 3.94 | 19.67 | 3.06 |
| Book Value | 75.60 | 57.60 | 60.95 | 29.59 | 39.71 | -8.05 | -4.36 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Zynerba Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
28 |
| CEO |
Armando Anido |
Stock Information
| Ticker Symbol |
ZYNE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: ZYNE |
| IPO Date |
August 5, 2015 |
Description
Zynerba Pharmaceuticals operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.